US Stock Movement: Eli Lilly surged on October 20 as Omvoh's pediatric indication and Phase III trial reached endpoints
Bitget异动解读2026/10/20 13:41Eli Lilly's Surge on October 20 Interpreted
Keywords: Omvoh pediatric indication, phase III trial reached endpoint
On October 19, Eli Lilly announced that the phase III SHINE-2 study of Omvoh for the treatment of pediatric ulcerative colitis had reached its primary endpoint; among 52 patients aged 6 to 17 who responded to Omvoh, 50% achieved clinical remission at week 52. The company plans to submit the study results to global regulatory agencies to seek an expansion of the drug’s indication.
(Disclaimer: This content is summarized from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Stock Movers: AGI surged on October 20 due to Santos FC sponsorship and increased brand exposure
Meta President Dina Powell McCormick will be responsible for external affairs
AMD collaborates with Intel to simplify AI development on x86 CPUs using PyTorch
Crypto prices
More
